Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (17)

2023

  1. Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

    JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846

  2. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

    Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898

2022

  1. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

  2. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  2. Trajectories of alcohol consumption during life and the risk of developing breast cancer

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176

2020

  1. Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study

    Scientific Reports, Vol. 10, Núm. 1

  2. Serum phospholipids fatty acids and breast cancer risk by pathological subtype

    Nutrients, Vol. 12, Núm. 10, pp. 1-18

2019

  1. SEOM clinical guidelines in early stage breast cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 18-30

2018

  1. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

    Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829

2017

  1. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study

    International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 3, pp. 473-480

  2. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts

    Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657

2016

  1. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck

    International Journal of Radiation Oncology Biology Physics, Vol. 94, Núm. 2, pp. 289-296

2012

  1. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

    Annals of Oncology, Vol. 23, Núm. 4, pp. 1016-1022

2011

  1. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: Efficacy and cardiac safety from the GEICAM/2004-05 study

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2591-2596

2007

  1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

2003

  1. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: A Cooperative Study by the GEICAM Group

    Clinical Breast Cancer, Vol. 3, Núm. 6, pp. 399-404